— Know what they know.
Not Investment Advice

RNA NASDAQ

Atrium Therapeutics, Inc.
1W: -1.7% 1M: -4.5% 3M: -82.1% YTD: -81.9% 1Y: -56.9% 3Y: +15.9% 5Y: -33.5%
$13.09
+0.05 (+0.38%)
 
Weekly Expected Move ±5.8%
$12 $12 $13 $14 $15
NASDAQ · Healthcare · Biotechnology · Alpha Radar Sell · Power 39 · $223.9M mcap · 16M float · 4.65% daily turnover · Short 41% of daily vol

Balance Sheet Trends

Total Assets
$278M +0.0% ▲
5Y CAGR: -3.6%
Total Liabilities
$71M +0.0% ▲
5Y CAGR: +20.8%
Shareholders Equity
$207M +0.0% ▲
5Y CAGR: -7.5%
Cash & Investments
$270M +0.0% ▲
5Y CAGR: -3.8%
Total Debt
$4M +0.0% ▲
5Y CAGR: +31.4%
Net Debt
-$266M +0.0% ▲

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2021FY2022FY2023FY2024FY2025
— Assets —
Cash$320M$340M$185M$220M$270M
Short-Term Investments$85M$270M$410M$1.3B$0
Cash & ST Investments$406M$611M$595M$1.5B$270M
Net Receivables$900K$4M$9M$28M$0
Inventory$0$0$0$0$0
Other Current Assets$0$0$0$0$1M
Total Current Assets$411M$623M$611M$1.5B$273M
Property, Plant & Equip.$16M$15M$17M$18M$6M
Goodwill & Intangibles$0$0$0$0$0
Long-Term Investments$0$0$0$0$0
Other Non-Current Assets$850K$849K$596K$3M$0
Total Non-Current Assets$16M$16M$17M$22M$6M
Total Assets$428M$639M$629M$1.6B$278M
— Liabilities —
Accounts Payable$3M$5M$9M$8M$4M
Short-Term Debt$0$0$0$0$0
Deferred Revenue$0$5M$28M$21M$22M
Other Current Liabilities$5M$11M$14M$4M$3M
Total Current Liabilities$30M$52M$81M$98M$42M
Long-Term Debt$0$0$0$0$0
Other Non-Current Liab.$7M$0$0$0$574K
Total Non-Current Liabilities$16M$9M$47M$41M$29M
Total Liabilities$46M$61M$128M$139M$71M
— Equity —
Common Stock$5K$7K$8K$12K$17K
Retained Earnings-$185M-$359M-$571M-$893M$0
Accumulated OCI-$187K-$3M$125K$3M$0
Total Stockholders Equity$381M$578M$501M$1.4B$207M
Total Liabilities & Equity$428M$639M$629M$1.6B$278M
— Key Metrics —
Total Debt$12M$11M$10M$7M$4M
Net Debt-$309M-$330M-$175M-$213M-$266M
Total Investments$85M$270M$410M$1.3B$0

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms